Detection of Autoantibodies Against Nucleoporin p62 in Sera of Patients With Primary Biliary Cholangitis
10.3343/alm.2019.39.3.291
- Author:
Alicja BAUER
1
;
Andrzej HABIOR
Author Information
1. Department of Biochemistry and Molecular Biology, Hepatology and Clinical Oncology, Centre of Postgraduate Medical Education, Warsaw, Poland. alabauer@wp.pl
- Publication Type:Original Article
- Keywords:
Nucleoporin p62;
Primary biliary cholangitis;
ELISA;
Autoantibodies;
Liver;
Recombinant protein
- MeSH:
Alkaline Phosphatase;
Autoantibodies;
Bilirubin;
Blood Donors;
Cholangitis;
Cholangitis, Sclerosing;
Enzyme-Linked Immunosorbent Assay;
Hepatitis, Autoimmune;
Humans;
Liver;
Liver Diseases;
Nuclear Pore Complex Proteins;
Odds Ratio;
Prevalence;
Sensitivity and Specificity
- From:Annals of Laboratory Medicine
2019;39(3):291-298
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Primary biliary cholangitis (PBC) is an autoimmune liver disease characterized by specific autoantibodies. We evaluated the prevalence of autoantibodies against nucleoporin p62 (anti-p62) in PBC patients' sera to determine whether it can be a marker for PBC, in comparison with other immunological and biochemical parameters. We validated the performance of our in-house ELISA technique. METHODS: Serum samples were collected from 135 PBC patients. Thirty patients with primary sclerosing cholangitis (PSC) and 30 with autoimmune hepatitis (AIH) were included as pathological controls, and 40 healthy blood donors served as healthy controls. The presence of anti-p62 was determined by an in-house ELISA using a recombinant protein. We calculated the sensitivity, specificity, positive and negative predictive values (PPV and NPV), and positive and negative likelihood ratio (LR+ and LR−) of our in-house ELISA for diagnosing PBC based on anti-p62. Findings were correlated with biochemical data and survival. RESULTS: Anti-p62 was detected in 32 PBC patients (23.7%). Specificity and PPV of anti-p62 for PBC were 99% and 97%, respectively. The difference between proportions of anti-p62-positive patients and controls was 0.23 (95% confidence interval [CI]: 0.03–0.40; P < 0.0001); LR+ and LR− were 23.7 and 0.77, respectively. The presence of anti-p62 was associated with higher levels of bilirubin and alkaline phosphatase (P < 0.001). The odds ratio for survival was 2.44 (95% CI: 0.87–6.87; P=0.091). CONCLUSIONS: Anti-p62 may be regarded as a significant serological marker of PBC.
